CANF
Can-Fite BioPharma Ltd.
Price Chart
Latest Quote
$2.98
-0.05 (-1.65%)
Current Price
| Previous Close | $3.03 |
| Open | $3.02 |
| Day High | $3.07 |
| Day Low | $2.98 |
| Volume | 8,334 |
Stock Information
| Shares Outstanding | 2.14M |
| Total Debt | $71K |
| Cash Equivalents | $8.54M |
| Revenue | $405K |
| Net Income | $-9.83M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.38M |
| EPS (TTM) | $-10.75 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-2.04M |
| Sales | $405K |
| Income | $-9.83M |
| Book/sh | $4.27 |
| Cash/sh | $3.99 |
| Employees | 5 |
Financial Ratios
| Quick Ratio | 3.13 |
| Current Ratio | 3.46 |
| Debt/Eq | 1.27 |
Returns & Margins
| ROA | -66.75% |
| ROE | -178.24% |
| Gross Margin | 100.00% |
| Operating Margin | -2488.67% |
Ownership
| Institutional Ownership | 6.55% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -11.46 |
| P/S | 15.76 |
| P/B | 0.70 |
Analyst Data
| Recommendation | none |
| Target Price | $5.00 |
Technical Indicators
| SMA20 | $3.13 |
| SMA50 | $3.15 |
| SMA200 | $5.92 |
| RSI | 29.67 |
| ATR | 0.1557 |
| Shares Float | 2.14M |
| Short Float | 3.18% |
| Short Ratio | 0.05 |
| Volatility | 0.01 |
| Rel Volume | 0.34 |
Performance History
| Week | +4.56% |
| Month | -8.31% |
| Quarter | -10.51% |
| 6 Months | -48.62% |
| YTD | -32.27% |
| Year | -85.81% |
| 3 Years | -94.93% |
| 5 Years | -99.34% |
| 10 Years | -99.96% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.98 | 9,400 |
| 2026-06-17 | $3.03 | 47,300 |
| 2026-06-16 | $3.00 | 17,300 |
| 2026-06-15 | $2.99 | 38,500 |
| 2026-06-12 | $2.84 | 27,300 |
| 2026-06-11 | $2.85 | 23,000 |
| 2026-06-10 | $2.82 | 10,900 |
| 2026-06-09 | $2.91 | 36,300 |
| 2026-06-08 | $3.08 | 16,900 |
| 2026-06-05 | $3.09 | 29,600 |
| 2026-06-04 | $3.16 | 7,600 |
| 2026-06-03 | $3.11 | 19,900 |
| 2026-06-02 | $3.11 | 90,000 |
| 2026-06-01 | $3.24 | 47,900 |
| 2026-05-29 | $3.35 | 18,400 |
| 2026-05-28 | $3.36 | 17,300 |
| 2026-05-27 | $3.35 | 14,500 |
| 2026-05-26 | $3.44 | 16,600 |
| 2026-05-22 | $3.40 | 45,500 |
| 2026-05-21 | $3.44 | 17,100 |
| 2026-05-20 | $3.46 | 7,100 |
| 2026-05-19 | $3.25 | 25,600 |
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
đ° Latest News
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
Zacks âĸ 2026-03-05T14:18:00Z
Sector Update: Health Care Stocks Edge Higher Late Afternoon
MT Newswires âĸ 2025-12-26T21:06:46ZSector Update: Health Care Stocks Lower in Friday Afternoon Trading
MT Newswires âĸ 2025-12-26T18:59:16ZTop Midday Stories: Nvidia-Groq Licensing Deal; Target Attracts Growing Interest From Toms Capital
MT Newswires âĸ 2025-12-26T17:10:34ZExchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Investors Await Clues on Fed's Interest Rate Cut
MT Newswires âĸ 2025-11-18T13:49:08Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $405,000 | $674,000 | $743,000 | $810,000 |
| Operating Revenue | $405,000 | $674,000 | $743,000 | $810,000 |
| Expenses | ||||
| Total Expenses | $10,355,000 | $8,804,000 | $8,938,000 | $10,906,000 |
| Other Income Expense | $-148,000 | $-27,000 | $69,000 | $-283,000 |
| Net Non Operating Interest Income Expense | $270,000 | $277,000 | $492,000 | $206,000 |
| Total Other Finance Cost | $14,000 | $14,000 | $14,000 | $16,000 |
| Operating Expense | $10,355,000 | $8,804,000 | $8,938,000 | $10,906,000 |
| General And Administrative Expense | $3,662,000 | $3,047,000 | $2,955,000 | $3,143,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-9,828,000 | $-7,880,000 | $-7,634,000 | $-10,173,000 |
| Net Interest Income | $270,000 | $277,000 | $492,000 | $206,000 |
| Interest Income | $284,000 | $291,000 | $506,000 | $222,000 |
| Normalized Income | $-9,680,000 | $-7,853,000 | $-7,703,000 | $-9,890,000 |
| Net Income From Continuing And Discontinued Operation | $-9,828,000 | $-7,880,000 | $-7,634,000 | $-10,173,000 |
| Total Operating Income As Reported | $-9,950,000 | $-8,130,000 | $-8,195,000 | $-10,096,000 |
| Net Income Common Stockholders | $-9,828,000 | $-7,880,000 | $-7,634,000 | $-10,173,000 |
| Net Income | $-9,828,000 | $-7,880,000 | $-7,634,000 | $-10,173,000 |
| Net Income Including Noncontrolling Interests | $-9,828,000 | $-7,880,000 | $-7,634,000 | $-10,173,000 |
| Net Income Continuous Operations | $-9,828,000 | $-7,880,000 | $-7,634,000 | $-10,173,000 |
| Pretax Income | $-9,828,000 | $-7,880,000 | $-7,634,000 | $-10,173,000 |
| Interest Income Non Operating | $284,000 | $291,000 | $506,000 | $222,000 |
| Operating Income | $-9,950,000 | $-8,130,000 | $-8,195,000 | $-10,096,000 |
| Per Share | ||||
| Diluted EPS | $-10.75 | $-19.55 | $-32.26 | $-60.00 |
| Basic EPS | $-10.75 | $-19.55 | $-32.26 | $-60.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-9,778,000 | $-8,096,000 | $-8,249,000 | $-9,799,000 |
| Total Unusual Items | $-148,000 | $-27,000 | $69,000 | $-283,000 |
| Total Unusual Items Excluding Goodwill | $-148,000 | $-27,000 | $69,000 | $-283,000 |
| Reconciled Depreciation | $24,000 | $7,000 | $15,000 | $14,000 |
| EBITDA (Bullshit earnings) | $-9,926,000 | $-8,123,000 | $-8,180,000 | $-10,082,000 |
| EBIT | $-9,950,000 | $-8,130,000 | $-8,195,000 | $-10,096,000 |
| Diluted Average Shares | $914,560 | $402,949 | $236,728 | $135,958 |
| Basic Average Shares | $914,560 | $402,949 | $236,728 | $135,958 |
| Diluted NI Availto Com Stockholders | $-9,828,000 | $-7,880,000 | $-7,634,000 | $-10,173,000 |
| Gain On Sale Of Security | $-148,000 | $-27,000 | $69,000 | $-283,000 |
| Research And Development | $6,693,000 | $5,757,000 | $5,983,000 | $7,763,000 |
| Selling General And Administration | $3,662,000 | $3,047,000 | $2,955,000 | $3,143,000 |
| Other Gand A | $3,662,000 | $3,047,000 | $2,955,000 | $3,143,000 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $0 |
| Tax Provision | - | - | $0 | $0 |
Fetched: 2026-06-12
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,592,000 | $5,436,000 | $6,243,000 | $4,472,000 |
| Total Assets | $9,514,000 | $9,120,000 | $9,989,000 | $9,283,000 |
| Total Non Current Assets | $74,000 | $138,000 | $81,000 | $126,000 |
| Current Assets | $9,440,000 | $8,982,000 | $9,908,000 | $9,157,000 |
| Other Current Assets | $900,000 | $1,095,000 | $986,000 | $1,170,000 |
| Cash Cash Equivalents And Short Term Investments | $8,540,000 | $7,887,000 | $8,922,000 | $7,987,000 |
| Cash And Cash Equivalents | $5,528,000 | $4,825,000 | $4,278,000 | $2,978,000 |
| Prepaid Assets | - | - | $908,000 | $1,123,000 |
| Receivables | - | - | - | $47,000 |
| Other Receivables | - | - | - | $47,000 |
| Debt | ||||
| Total Debt | $71,000 | $104,000 | $40,000 | $62,000 |
| Long Term Debt And Capital Lease Obligation | $15,000 | $51,000 | $13,000 | $14,000 |
| Current Debt And Capital Lease Obligation | $56,000 | $53,000 | $27,000 | $48,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,922,000 | $3,684,000 | $3,746,000 | $4,811,000 |
| Total Non Current Liabilities Net Minority Interest | $1,191,000 | $1,632,000 | $1,726,000 | $2,309,000 |
| Non Current Deferred Liabilities | $1,176,000 | $1,581,000 | $1,713,000 | $2,295,000 |
| Current Liabilities | $2,731,000 | $2,052,000 | $2,020,000 | $2,502,000 |
| Current Deferred Liabilities | $405,000 | $405,000 | $622,000 | $783,000 |
| Payables And Accrued Expenses | $1,459,000 | $919,000 | $677,000 | $1,179,000 |
| Payables | $1,161,000 | $618,000 | $427,000 | $896,000 |
| Accounts Payable | $1,161,000 | $618,000 | $427,000 | $896,000 |
| Equity | ||||
| Common Stock Equity | $5,592,000 | $5,436,000 | $6,243,000 | $4,472,000 |
| Total Equity Gross Minority Interest | $5,592,000 | $5,436,000 | $6,243,000 | $4,472,000 |
| Stockholders Equity | $5,592,000 | $5,436,000 | $6,243,000 | $4,472,000 |
| Gains Losses Not Affecting Retained Earnings | $1,127,000 | $1,127,000 | $1,127,000 | $1,127,000 |
| Other Equity Adjustments | $1,127,000 | $1,127,000 | $1,127,000 | $1,127,000 |
| Retained Earnings | $-176,189,000 | $-166,361,000 | $-158,481,000 | $-150,847,000 |
| Other | ||||
| Ordinary Shares Number | $2,618,425 | $994,393 | $453,279 | $271,915 |
| Share Issued | $2,618,425 | $994,393 | $453,279 | $271,915 |
| Tangible Book Value | $5,592,000 | $5,436,000 | $6,243,000 | $4,472,000 |
| Invested Capital | $5,592,000 | $5,436,000 | $6,243,000 | $4,472,000 |
| Working Capital | $6,709,000 | $6,930,000 | $7,888,000 | $6,655,000 |
| Capital Lease Obligations | $71,000 | $104,000 | $40,000 | $62,000 |
| Total Capitalization | $5,592,000 | $5,436,000 | $6,243,000 | $4,472,000 |
| Additional Paid In Capital | $180,654,000 | $170,670,000 | $163,597,000 | $154,192,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $1,176,000 | $1,581,000 | $1,713,000 | $2,295,000 |
| Long Term Capital Lease Obligation | $15,000 | $51,000 | $13,000 | $14,000 |
| Current Deferred Revenue | $405,000 | $405,000 | $622,000 | $783,000 |
| Current Capital Lease Obligation | $56,000 | $53,000 | $27,000 | $48,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $811,000 | $675,000 | $694,000 | $492,000 |
| Current Accrued Expenses | $298,000 | $301,000 | $250,000 | $283,000 |
| Net PPE | $74,000 | $138,000 | $81,000 | $126,000 |
| Accumulated Depreciation | $-12,000 | $-52,000 | $-263,000 | $-248,000 |
| Gross PPE | $86,000 | $190,000 | $344,000 | $374,000 |
| Other Properties | $69,000 | $175,000 | $62,000 | $62,000 |
| Machinery Furniture Equipment | $17,000 | $15,000 | $269,000 | $299,000 |
| Other Short Term Investments | $3,012,000 | $3,062,000 | $4,644,000 | $5,009,000 |
| Leases | - | $0 | $13,000 | $13,000 |
| Properties | - | $0 | $0 | $0 |
Fetched: 2026-06-12
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,951,000 | $-7,642,000 | $-8,442,000 | $-10,810,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,949,000 | $-7,637,000 | $-8,440,000 | $-10,801,000 |
| Cash Flow From Continuing Operating Activities | $-8,949,000 | $-7,637,000 | $-8,440,000 | $-10,801,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-2,000 | $-5,000 | $-2,000 | $-9,000 |
| Investing Cash Flow | $-2,000 | $1,495,000 | $498,000 | $9,502,000 |
| Cash Flow From Continuing Investing Activities | $-2,000 | $1,495,000 | $498,000 | $9,502,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $9,644,000 | $6,711,000 | $9,144,000 | $0 |
| Financing Cash Flow | $9,644,000 | $6,711,000 | $9,144,000 | $0 |
| Cash Flow From Continuing Financing Activities | $9,644,000 | $6,711,000 | $9,144,000 | $0 |
| Net Common Stock Issuance | $9,644,000 | $6,711,000 | $9,144,000 | $0 |
| Common Stock Issuance | $9,644,000 | $6,711,000 | $9,144,000 | $0 |
| Other | ||||
| End Cash Position | $5,528,000 | $4,825,000 | $4,278,000 | $2,978,000 |
| Beginning Cash Position | $4,825,000 | $4,278,000 | $2,978,000 | $4,390,000 |
| Effect Of Exchange Rate Changes | $10,000 | $-22,000 | $98,000 | $-113,000 |
| Changes In Cash | $693,000 | $569,000 | $1,202,000 | $-1,299,000 |
| Net Investment Purchase And Sale | $0 | $1,500,000 | $500,000 | $9,511,000 |
| Net PPE Purchase And Sale | $-2,000 | $-5,000 | $-2,000 | $-9,000 |
| Purchase Of PPE | $-2,000 | $-5,000 | $-2,000 | $-9,000 |
| Change In Working Capital | $433,000 | $-267,000 | $-943,000 | $-1,301,000 |
| Change In Other Working Capital | $-405,000 | $-349,000 | $-743,000 | $-810,000 |
| Change In Other Current Liabilities | $-33,000 | $-32,000 | $-84,000 | $-62,000 |
| Change In Payables And Accrued Expense | $676,000 | $223,000 | $-300,000 | $-188,000 |
| Change In Payable | $676,000 | $223,000 | $-300,000 | $-188,000 |
| Change In Account Payable | $543,000 | $191,000 | $-469,000 | $-58,000 |
| Change In Prepaid Assets | $195,000 | $-109,000 | $184,000 | $-241,000 |
| Other Non Cash Items | $36,000 | $90,000 | $-222,000 | $113,000 |
| Stock Based Compensation | $340,000 | $362,000 | $261,000 | $263,000 |
| Unrealized Gain Loss On Investment Securities | $4,000 | $14,000 | $-11,000 | $229,000 |
| Asset Impairment Charge | $42,000 | $37,000 | $94,000 | $54,000 |
| Depreciation Amortization Depletion | $24,000 | $7,000 | $15,000 | $14,000 |
| Depreciation And Amortization | $24,000 | $7,000 | $15,000 | $14,000 |
| Depreciation | $24,000 | $7,000 | $15,000 | $14,000 |
| Net Income From Continuing Operations | $-9,828,000 | $-7,880,000 | $-7,634,000 | $-10,173,000 |
| Interest Paid Supplemental Data | - | - | $0 | $0 |
| Purchase Of Investment | - | - | - | - |
| Change In Other Current Assets | - | - | - | - |
| Net Foreign Currency Exchange Gain Loss | - | - | - | - |
Fetched: 2026-06-12